Background: EXPERT and EXPERT-C were prospective phase II clinical trials of neoadjuvant
Introduction
Short-course radiotherapy (RT) or long-course chemoradiotherapy (CRT) followed by surgery are established treatments for locally advanced rectal cancer (LARC) (1) . The increased ability to stratify patients by prognostic factors at baseline or response to neoadjuvant treatment has recently led to a reappraisal of this multimodality approach. Risk-adapted strategies have been investigated to reduce treatment-related toxicities and deterioration of quality of life (QoL) while maintaining satisfactory oncological outcomes. These include surgery alone for tumours with limited extramural invasion, neoadjuvant chemotherapy (NACT) alone for intermediate-risk tumours and omission of surgery after CRT-induced clinical complete response (CR) (2) .
While treatment de-escalation is worth pursuing in low-risk tumours, patients with poor baseline prognostic features may benefit from intensified neoadjuvant treatments (3) . Adding radiosensitising agents to fluoropyrimidines has largely failed to demonstrate superiority over standard CRT (4) . Administering NACT before CRT, however, is an attractive option with the potential to improve the outcome of high-risk LARC. Increased tumour downsizing/downstaging, early treatment of micrometastases, good patient compliance and in vivo assessment of tumour sensitivity are some of the theoretical advantages of this approach. Nevertheless, its routine use has been prevented by the lack of randomised phase III trials.
PAN-EX is a pooled analysis of individual patient data from EXPERT and EXPERT-C, two phase II trials of NACT followed by CRT in high-risk LARC (5, 6) . This study aims to provide detailed information on short-and long-term outcomes of the largest prospective series of patients treated with this intensified neoadjuvant treatment and to assess a number of prognostic factors.
Methods

Study and patient characteristics
All eligible patients enrolled in EXPERT and EXPERT-C were included. In both studies eligibility was limited to patients with ≥1 of the following on baseline high-resolution pelvic MRI: tumour ≤1 mm of the mesorectal fascia (MRF), extramural invasion >5 mm (T3c/d), T4, T3 at/below levators. N2 and extramural venous invasion (EMVI) were additional inclusion criteria in EXPERT and EXPERT-C, respectively. Study designs and treatment regimens are reported in Supplementary   Figure 1 . According to both EXPERT and EXPERT-C study protocols pelvic MRI scans had to be performed at baseline, within the last week of the first 12 weeks of NACT and 4 weeks after completion of CRT. These were reviewed independently by one radiologist (G.B.). Patients were followed-up for 5 years (5, 6). We have previously reported survival outcomes for the EXPERT and EXPERT-C studies after a median follow-up of 55 and 63.8 months, respectively (5, 7). The current analysis has been conducted using extended follow-up data (74.5 months for EXPERT and 71.3 months for EXPERT-C). Tumour downstaging was defined as reduction of ≥1 level in T or N staging between baseline and post-CRT MRI or histopathological staging. mrTRG was defined as previously reported (8) . pTRG was scored according to the Dworak system (9) . Given that 88% concordance of tumour differentiation among paired specimens was found, in order to minimise the effect of random histological sampling, grade of resected tumour was used whenever the corresponding baseline biopsy was not available or tumour differentiation was discordant between paired samples.
Prognostic variables
Statistical analysis
The primary objective was overall survival (OS) in the intention-to-treat (ITT) population. Kaplan Meier method, univariate and multivariate Cox regression models were used. Multivariate models were built to assess the prognostic significance of the above mentioned variables for all outcome measures in both the ITT and R0/R1 resection population. Variables with a P-value ≤0.1 from univariate analyses were entered into multivariate models (forward selection method) where only those with a P-value ≤0.05 following adjustment for other prognostic variables were considered statistically significant. The concordance index by Gönen & Heller was used to assess the accuracy of short-term outcome measures in predicting RFS and OS in R0/R1 patients (higher index=higher discriminatory power).
Results
269 patients were included. Table 1 Prognostic factors after univariate analyses are reported in Supplementary Tables 1-8. Table 3 shows those that remained significant after multivariate analyses.
The prognostic value of mrTRG after each treatment phase was further investigated in the ITT population. Overall, 227 and 230 patients were assessable for mrTRG after NACT and CRT, respectively. mrTRG after NACT was associated with a statistically significant difference in PFS Further to the Cox regression analyses we calculated the c-index for a number of short-term outcome measures to assess their prognostic accuracy in R0/R1 patients (Supplementary Table 9 ).
191 patients were assessable for the variables considered. Among these, ypT0-2 (Supplementary 
Discussion
A number of interesting findings have emerged from this analysis. We have confirmed that 9 administering systemic chemotherapy before CRT is associated with good patient compliance, high rates of tumour response/downstaging and microscopically radical resection. Encouraging rates of both local and distant tumour control were also observed especially considering the high-risk patient population. In line with previous studies, survival was better for those patients who completed the full course of study treatment (10).
Assessment of toxicity and QoL was not included in this study and one could argue that the potential advantages of intensifying neoadjuvant therapies may come with the price of a detrimental effect on these important outcome measures. However, we have previously shown that toxicity was not an issue (5, 6) . Moreover, in a recent analysis of the EXPERT-C trial (which accounted for 61%
of the PAN-EX population) QoL and bowel function did not appear to be significantly affected in both the short and the long term (11) . Nevertheless, the absence of a control group of standard CRT limits the general applicability of our results and a definitive conclusion on the role of NACT in high-risk LARC can only be provided by randomised phase III trials.
Detection of risk factors and implementation of risk-adapted strategies are considered paramount in the management of RC especially following the routine adoption of MRI for tumour staging and assessment of response to treatment. In this context, the results of PAN-EX may provide valuable insights into the potential role of several factors in the decision-making process for LARC.
Although all patients included in this analysis had high-risk tumours by study eligibility criteria, we were able to identify independent baseline prognostic variables such as age, tumour grade and mrEMVI that may be given consideration for use as stratification factors in future clinical studies conducted in similar populations. Furthermore, the availability of MRI scans taken after each phase of treatment allowed us to assess the prognostic value of dynamic, imaging-based, indicators of response at different time points. In line with our previous data in patients treated with standard
CRT (8), we demonstrated that, even in the setting of an intensified neoadjuvant treatment, absence of tumour signal/minimal residual tumour before surgery is a favourable prognostic factor. More interestingly, for the first time, we showed that mrTRG after systemic chemotherapy correlated with long-term outcome and could serve as a valuable tool to predict the probability of gaining incremental benefit from sequential CRT and to estimate the magnitude of this.
These results are of significant value if we consider that a strong interest has recently emerged for the investigation of preoperative strategies where the use of CRT is restricted to those patients who do not achieve a satisfactory response to upfront systemic chemotherapy (2). However, validated criteria to discriminate between responders and nonresponders to chemotherapy are lacking.
Although the relatively small samples size and the design of PAN-EX (i.e., all patients received CRT) recommend caution in the interpretation of our findings, this study suggests that patients who achieve intermediate tumour regression (mrTRG3) after NACT may be more likely to benefit from the use of sequential CRT compared to those who achieve complete/good (mrTRG1/2) or poor (mrTRG4/5) tumour regression who may have only a marginal incremental survival advantage.
Future studies are needed to confirm this hypothesis and also to investigate whether assessment of response to upfront systemic chemotherapy by using mrTRG could be used to select patients for ACT. It should be noted, however, that the relatively early timing of response assessment before surgery (i.e.,4 weeks after completion of CRT) might have had an impact on capturing the highest degree of tumour regression and possibly precluded a shift of patients towards more prognostically favourable mrTRG categories. Moreover, although previous studies support the contention that imaging-based assessment of tumour regression is reproducible with moderate to substantial interobserver agreement, MRI scans in this study were reviewed by a highly experienced radiologist and generalisability of our results has to be confirmed.
The results of PAN-EX may also potentially challenge two important assumptions in LARC: the routine use of CRT in tumours involving/threatening the MRF and the choice of pCR as surrogate endpoint for phase II trials. In our series approximately 35% of patients who had tumours <1 mm of the MRF at baseline were found to have a safe MRF after 3 months of NACT. These figures confirm the ability of chemotherapy to downsize the primary tumour and suggest that some of these high-risk patients may possibly proceed to surgery directly after systemic treatment and be spared from acute toxicities and long-term side effects of radiotherapy. However, validation of this hypothesis in studies investigating the correlation between imaging, histopathological findings and long-term outcomes is needed. Interestingly, when we analysed the prognostic value of a number of surgical/pathological variables in the curatively resected population, only ypT stage was found to independently predict survival. In an exploratory concordance analysis, ypT appeared also to have higher discriminatory power for long-term outcomes than pCR, this supporting the contention that alternative short-term outcome measures could perform better than pCR in assessing the impact on survival of novel intensified neoadjuvant treatment strategies in phase II LARC trials.
We acknowledge that our study has a number of limitations. EXPERT and EXPERT-C were sequential trials that spanned over a period of 7 years. Differences in terms of treatment and procedures between these trials as well as the improvement over time of the quality of imaging, surgery and pathology suggest that these patient populations are not entirely comparable. The retrospective assessment of some of the variables investigated may have introduced biases and, due
to the large number of variables and outcome measures considered, the analysis of prognostic factors should be regarded as exploratory. Moreover, the lack of appropriate control groups makes our proposed interpretations of some of the study findings speculative in nature. However, the analysis of this largely homogeneous prospective series of high-risk LARC patients offers a unique opportunity to further explore the role NACT followed by CRT in this setting and provides a valuable platform for the generation of hypotheses to test in future prospective clinical trials.
Biomarker analyses in this patient population are ongoing and will hopefully lead to another step forward in the adoption of risk-adapted treatment strategies for LARC. Table 2 . Imaging-based response to neoadjuvant treatment in the ITT population (n = 269) and pathological findings at surgery in the resected (R0-2) population (n = 244) Table 3 . Significant prognostic factors after multivariate analyses Table 4 . Survival outcomes by mrTRG post-NACT (n = 227) and mrTRG post-CRT (n = 230) in the ITT population
